• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2018年艾滋病治愈相关临床试验和观察性研究的全景分析。

A landscape analysis of HIV cure-related clinical trials and observational studies in 2018.

作者信息

Barr Liz, Jefferys Richard

机构信息

Women's HIV Research Collaborative (WHRC), AIDS Clinical Trials Group Community Scientific Subcommittee (ACTG CSS), Baltimore, MD, USA.

Department of Gender, Women's, and Sexuality Studies University of Maryland, Baltimore County (UMBC), Baltimore, MD, USA.

出版信息

J Virus Erad. 2019 Nov 4;5(4):212-219. doi: 10.1016/S2055-6640(20)30030-3.

DOI:10.1016/S2055-6640(20)30030-3
PMID:31754444
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6844401/
Abstract

OBJECTIVES

The community-based organisation Treatment Action Group has established an online listing of HIV cure-related trials and observational studies derived from trial registries. Our objective was to use the listing as a basis for a landscape analysis of the current status of HIV cure-related clinical research.

METHODS

Trials and observational studies listed as of August 2018 formed the sample set. Survey questions were developed on trial development, trial design, recruitment, enrolment, study completion and dissemination plans. A survey was sent to the contact(s) for each study. Supplemental information was collected from clinicaltrials.gov. The full dataset was then analysed.

RESULTS

A total of 99 interventional trials and 29 observational studies were included. Diverse interventions are under evaluation, including combinations of experimental candidates. Current studies plan to enrol over 7000 participants. Projected completion dates for ~90% of the sample fell between the fourth quarter of 2018 and the end of 2020. Potential obstacles to enrolment that were reported included concerns over invasive procedures and lack of potential benefit to participants. Data on the sex and ethnicity of enrollees were limited but sufficient to note a significant under-representation of women.

CONCLUSIONS

A considerable amount of HIV cure-related clinical research is under way. The results from these studies, which should help shape the future of the field, will become available over the next 2-4 years. Diversity both geographically and in terms of enrollees remains limited, particularly in terms of the participation of women, a concern that could significantly affect the generalisability of the findings.

摘要

目的

社区组织治疗行动组织建立了一个源自试验注册库的与HIV治愈相关试验和观察性研究的在线列表。我们的目标是以该列表为基础,对与HIV治愈相关的临床研究现状进行态势分析。

方法

截至2018年8月列出的试验和观察性研究构成样本集。针对试验开展、试验设计、招募、入组、研究完成及传播计划制定了调查问卷。向每项研究的联系人发送了调查问卷。从美国国立医学图书馆临床试验数据库收集了补充信息。然后对完整数据集进行分析。

结果

共纳入99项干预性试验和29项观察性研究。正在评估多种干预措施,包括实验候选药物的组合。当前研究计划招募7000多名参与者。约90%的样本预计完成日期在2018年第四季度至2020年底之间。报告的潜在招募障碍包括对侵入性程序的担忧以及对参与者缺乏潜在益处。关于入组者性别和种族的数据有限,但足以注意到女性代表性严重不足。

结论

大量与HIV治愈相关的临床研究正在进行。这些研究的结果将在未来2至4年内得出,应有助于塑造该领域的未来。地域和入组者方面存在的多样性仍然有限,尤其是女性的参与情况,这一问题可能会严重影响研究结果的普遍性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc1e/6844401/75fe0e99c94d/jve-5-212-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc1e/6844401/286e6b67e8fc/jve-5-212-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc1e/6844401/75fe0e99c94d/jve-5-212-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc1e/6844401/286e6b67e8fc/jve-5-212-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc1e/6844401/75fe0e99c94d/jve-5-212-g002.jpg

相似文献

1
A landscape analysis of HIV cure-related clinical trials and observational studies in 2018.2018年艾滋病治愈相关临床试验和观察性研究的全景分析。
J Virus Erad. 2019 Nov 4;5(4):212-219. doi: 10.1016/S2055-6640(20)30030-3.
2
A landscape analysis of HIV cure-related clinical research in 2019.2019年艾滋病治愈相关临床研究的景观分析。
J Virus Erad. 2020 Sep 2;6(4):100010. doi: 10.1016/j.jve.2020.100010. eCollection 2020 Nov.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).人重组 C1 酯酶抑制剂(康奈司他)预防 COVID-19 住院患者严重 SARS-CoV-2 感染的研究方案:一项随机、平行分组、开放标签、多中心试验的结构摘要(PROTECT-COVID-19)。
Trials. 2021 Jan 4;22(1):1. doi: 10.1186/s13063-020-04976-x.
5
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.COVID-19 门诊患者的早期抗病毒治疗(FLARE):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 8;22(1):193. doi: 10.1186/s13063-021-05139-2.
6
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
7
Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.伴有确诊的 2019 冠状病毒病(COVID-19)感染住院患者肾素-血管紧张素-醛固酮系统阻滞剂管理(麦吉尔 RAAS-COVID-19):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Feb 5;22(1):115. doi: 10.1186/s13063-021-05080-4.
8
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.一项评估巴瑞替尼预防 COVID19 相关血液肿瘤患者呼吸功能不全进展的疗效的 I/II 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Feb 5;22(1):116. doi: 10.1186/s13063-021-05072-4.
9
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
10
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.用于评估非住院轻中度 COVID-19 患者肠道微生物组调节的自然史和影响的虚拟化临床研究:一项随机、开放标签、前瞻性研究,平行组研究评估 KB109 对肠道微生物组结构和功能的生理影响:一项随机对照研究方案的结构化总结。
Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.

引用本文的文献

1
Resolving Challenges in HIV Cure-Related Research: Protocol for a Modified Delphi Consensus-Building Process.解决艾滋病治愈相关研究中的挑战:改进的德尔菲共识构建过程方案
JMIR Res Protoc. 2025 Aug 6;14:e67123. doi: 10.2196/67123.
2
Centring the health of women across the HIV research continuum.将妇女健康置于艾滋病病毒研究连续体的中心。
Lancet HIV. 2024 Mar;11(3):e186-e194. doi: 10.1016/S2352-3018(24)00004-3.
3
Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.

本文引用的文献

1
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.抗逆转录病毒治疗中断分析在 HIV 研究试验中的建议——共识会议报告。
Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15.
2
Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation.基于性别的人类免疫缺陷病毒 1 型储存库活性和残留免疫激活的差异。
J Infect Dis. 2019 Mar 15;219(7):1084-1094. doi: 10.1093/infdis/jiy617.
3
It is not just about "the trial": the critical role of effective engagement and participatory practices for moving the HIV research field forward.
美国费城一项延长分析性治疗中断的 HIV 治愈导向试验中的参与者体验。
HIV Res Clin Pract. 2023 Oct 6;24(1):2267825. Epub 2023 Oct 14.
4
Increasing the meaningful involvement of women in HIV cure-related research: a qualitative interview study in the United States.提高女性在 HIV 治愈相关研究中的实质性参与度:美国的一项定性访谈研究。
HIV Res Clin Pract. 2023 Aug 8;24(1):2246717.
5
'With this study, we have hope that something is coming': community members' perceptions of HIV cure-related research in Durban, South Africa - a qualitative focus group study.“通过这项研究,我们看到了希望:”南非德班社区成员对艾滋病治愈相关研究的看法——一项定性焦点小组研究。
HIV Res Clin Pract. 2023 Jul 29;24(1):2243046.
6
Application of ultrasensitive digital ELISA for p24 enables improved evaluation of HIV-1 reservoir diversity and growth kinetics in viral outgrowth assays.超敏数字 ELISA 法检测 p24 可提高病毒扩增试验中 HIV-1 储存库多样性和生长动力学的评估效果。
Sci Rep. 2023 Jul 6;13(1):10958. doi: 10.1038/s41598-023-37223-9.
7
The Importance of Social Engagement in the Development of an HIV Cure: A Systematic Review of Stakeholder Perspectives.社会参与在艾滋病治愈发展中的重要性:对利益相关者观点的系统综述
AIDS Behav. 2023 Nov;27(11):3789-3812. doi: 10.1007/s10461-023-04095-z. Epub 2023 Jun 17.
8
A partner protection package for HIV cure-related trials involving analytical treatment interruptions.涉及分析性治疗中断的 HIV 治愈相关试验的合作伙伴保护方案。
Lancet Infect Dis. 2023 Oct;23(10):e418-e430. doi: 10.1016/S1473-3099(23)00267-0. Epub 2023 Jun 6.
9
Short Communication: Population Representation in HIV Cure Research: A Review of Diversity Within HIV Cure Studies Based in the United States.短篇通讯:HIV 治愈研究中的人群代表性:对美国开展的 HIV 治愈研究中多样性的综述。
AIDS Res Hum Retroviruses. 2022 Aug;38(8):631-644. doi: 10.1089/AID.2021.0127. Epub 2022 Feb 21.
10
Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.考虑在 HIV 治愈相关研究中增加种族、民族、性别和性多样性,包括分析性治疗中断:定性研究。
AIDS Res Hum Retroviruses. 2022 Jan;38(1):50-63. doi: 10.1089/AID.2021.0023. Epub 2021 May 31.
这不仅仅关乎“试验”:有效参与和参与式实践在推动艾滋病研究领域发展中的关键作用。
J Int AIDS Soc. 2018 Oct;21 Suppl 7(Suppl Suppl 7):e25179. doi: 10.1002/jia2.25179.
4
Strengthening stakeholder engagement through ethics review in biomedical HIV prevention trials: opportunities and complexities.通过生物医学 HIV 预防试验中的伦理审查加强利益攸关方的参与:机会与复杂性。
J Int AIDS Soc. 2018 Oct;21 Suppl 7(Suppl Suppl 7):e25172. doi: 10.1002/jia2.25172.
5
Brief Report: Safety and Tolerability of Inguinal Lymph Node Biopsy in Individuals With Acute HIV Infection in Thailand.简报:泰国急性 HIV 感染个体腹股沟淋巴结活检的安全性和耐受性。
J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):244-248. doi: 10.1097/QAI.0000000000001780.
6
Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir.雌激素受体 1 是 HIV-1 潜伏期的关键调节因子,它对潜伏储库赋予了性别特异性的限制。
Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7795-E7804. doi: 10.1073/pnas.1803468115. Epub 2018 Jul 30.
7
Post-treatment and spontaneous HIV control.治疗后及自然控制的 HIV。
Curr Opin HIV AIDS. 2018 Sep;13(5):402-407. doi: 10.1097/COH.0000000000000488.
8
Sex Differences in HIV Infection.HIV 感染中的性别差异。
Curr HIV/AIDS Rep. 2018 Apr;15(2):136-146. doi: 10.1007/s11904-018-0383-2.
9
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.一项在感染早期开始接受抗逆转录病毒治疗的 HIV 感染者中进行的治疗性疫苗接种的随机对照安全性/疗效试验。
Sci Transl Med. 2017 Dec 6;9(419). doi: 10.1126/scitranslmed.aan8848.
10
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.急性HIV-1感染期间极早期开始抗逆转录病毒治疗(ART)后HIV-1的持续存在:一项观察性研究。
PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.